EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access

Validation of the REverSe TRanscrIptase Chain Termination assay for measuring tenofovir diphosphate in dried blood spots from a clinical pharmacokinetic trial

Benjamin P Sullivan, Cosette A Craig, Andrew T Bender, Emily Blake, Oraphan Siriprakaisil, Pra-Ornsuda Sukrakanchana, Tim R Cressey, Paul K Drain iD, Ayokunle O Olanrewaju, Jonathan D Posner iD

Journal of Antimicrobial Chemotherapy · 02.04.2025 · 80 (4) · 1141-1147

DOI: 10.1093/jac/dkaf049 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 25.02.2025. Verfasst von Benjamin P Sullivan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mechanical Engineering, University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: Adenine, HIV Infections, Dried Blood Spot Testing, Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI, NIGMS, NICHD.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tenofovir diphosphate concentration in red blood cells is an objective measure of long-term oral pre-exposure prophylaxis (PrEP) or antiretroviral therapy (ART) adherence. However, current methods for measuring tenofovir diphosphate are equipment and capital intensive, limiting widespread adoption.

Objectives

Low cost, rapid diagnostics for measuring tenofovir diphosphate may drive clinical adoption of routine drug level measurement as a tool for adherence monitoring of tenofovir disoproxil fumarate-based PrEP or ART. We validate a simple and accessible enzymatic assay [REverSe TRanscrIptase Chain Termination (RESTRICT)] for measuring tenofovir diphosphate in dried blood spots (DBS) obtained from a directly observed therapy study of individuals on PrEP.

Methods

We performed RESTRICT measurements on 74 DBS samples from individuals on tenofovir disoproxil fumarate/emtricitabine regimens. We compared RESTRICT measurements with those from a gold-standard method of liquid chromatography tandem mass spectrometry (LC-MS/MS). The ability of RESTRICT to correctly classify DBS tenofovir diphosphate concentrations to established steady-state adherence benchmark concentrations was determined using area under receiver operating characteristic curves (AUCs).

Results

The RESTRICT measurements of DBS samples were highly correlated with LC-MS/MS measurements of tenofovir diphosphate from DBS (r = −0.90; P < 0.0001). The RESTRICT assay correctly classified DBS samples as above or below established steady-state adherence benchmark concentrations corresponding to low (AUC = 0.974), moderate (AUC = 0.936) and high (AUC = 0.955) levels of adherence.

Conclusions

The enzymatic RESTRICT assay can accurately measure tenofovir diphosphate concentrations in DBS specimens using simple procedures and readily available laboratory equipment, offering accessible objective adherence monitoring for persons receiving tenofovir disoproxil fumarate-based PrEP or ART.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenineHIV InfectionsDried Blood Spot TestingAnti-HIV AgentsOrganophosphatesDrug MonitoringTenofovirHumansTandem Mass SpectrometryChromatography, LiquidPre-Exposure ProphylaxisMaleEmtricitabineFemale

Substanzen

tenofovir diphosphateAdenineAnti-HIV AgentsOrganophosphatesTenofovirEmtricitabine

Autor:innen und Institutionen

  • Department of Mechanical Engineering, University of Washington, Seattle, WA, USA.
  • Department of Bioengineering, University of Washington, Seattle, WA, USA.
  • Department of Medicine, Sanpatong Hospital, Chiang Mai, Thailand.
  • AMS-PHPT Research Collaboration, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
  • Department of Epidemiology, University of Washington, Seattle, WA, USA.
  • Department of Global Health, University of Washington, Seattle, WA, USA.

ORCID-Profile: Paul K Drain, Jonathan D Posner

Förderung

  • NHLBI
  • NIGMS
  • NICHD
  • NIAID NIH HHS
  • NIAID
  • University of Washington/Fred Hutch Center
  • NCI
  • NIA

Zitieren

APA

Sullivan, B. P., Craig, C. A., Bender, A. T., Blake, E., Siriprakaisil, O., Sukrakanchana, P. O., Cressey, T. R., Drain, P. K., Olanrewaju, A. O., & Posner, J. D. (2025). Validation of the REverSe TRanscrIptase Chain Termination assay for measuring tenofovir diphosphate in dried blood spots from a clinical pharmacokinetic trial. Journal of Antimicrobial Chemotherapy, 80(4), 1141-1147. https://doi.org/10.1093/jac/dkaf049

Vancouver

Sullivan BP, Craig CA, Bender AT, Blake E, Siriprakaisil O, Sukrakanchana PO, et al. Validation of the REverSe TRanscrIptase Chain Termination assay for measuring tenofovir diphosphate in dried blood spots from a clinical pharmacokinetic trial. Journal of Antimicrobial Chemotherapy. 2025;80(4):1141-1147. doi:10.1093/jac/dkaf049

BibTeX
@article{Sullivan2025,
  author = {Sullivan, Benjamin P and Craig, Cosette A and Bender, Andrew T and Blake, Emily and Siriprakaisil, Oraphan and Sukrakanchana, Pra-Ornsuda and Cressey, Tim R and Drain, Paul K and Olanrewaju, Ayokunle O and Posner, Jonathan D},
  title = {Validation of the REverSe TRanscrIptase Chain Termination assay for measuring tenofovir diphosphate in dried blood spots from a clinical pharmacokinetic trial},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {4},
  pages = {1141--1147},
  doi = {10.1093/jac/dkaf049}
}
Kostenlos starten →